ATC Φάρμακα Δραστικές ICPC2 ICD10 Ιατρική στην Πράξη Νοσήματα Λοιμώξεις Εμβόλια Πρωτόκολλα
  • Nepafenac
  • indication:For the treatment of pain and inflammation associated with cataract surgery.
  • pharmacologypharmacology:
  • mechanism: Nepafenac is a prodrug. After penetrating the cornea, nepafenac undergoes rapid bioactivation to amfenac, which is a potent NSAID that uniformly inhibits the COX1 and COX2 activity.
  • toxicity: Ocularly applied non-steroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.
  • absorprion: Nepafenac rapidly cross the cornea (6 times faster than diclofenac in vitro).
  • halflife:
  • roouteelimination: After oral administration of 14C-nepafenac to healthy volunteers, urinary excretion was found to be the major route of radioactivity elimination, accounting for approximately 85% of the dose, while fecal excretion represented approximately 6% of the dose. Nepafenac (prodrug) and amfenac (active compound) were not quantifiable in the urine.
  • volumedistribution:
  • clearance: